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Abstract
Background: Studies in recent years have shown that undercarboxylated osteocalcin (uOC) not only maintains
bone mineralization, but is also involved in the regulation of atherosclerosis. However, a correlation between uOC
and carotid atherosclerosis in non-dialysis patients with chronic kidney disease (CKD) has not been investigated.
A total of 240 non-dialysis patients with CKD were included in the study. For these patients, the median estimated
glomerular filtration rate (eGFR) was 20.05 (12.43–49.32) ml/min/1.73m2. Serum uOC levels were measured using
enzyme-linked immunosorbent assay (ELISA). Carotid ultrasonography was performed to assess carotid
atherosclerotic plaques and intima–media thickness (IMT) in an attempt to analyze the relationship between uOC
level and carotid atherosclerosis.
Results: The uOC levels of non-dialysis patients with CKD were significantly lower than those of healthy controls
[28.16 (21.40–45.85) ng/mL vs. 36.42 (28.05–49.28) ng/mL, P < 0.01]. The uOC levels gradually decreased as CKD
progressed (P < 0.01). The uOC levels were significantly lower in patients with carotid plaques than in patients without
carotid plaques [25.98 (20.14–31.35) ng/mL vs. 31.02 (25.86–36.40) ng/mL, P < 0.01]. uOC level showed significant negative
correlation with IMT (r = -0.33, P < 0.01). Logistic regression analysis revealed that after adjustment for various confounding
factors, decreased uOC levels were shown to indicate increased possibility of carotid atherosclerotic plaque development
in non-dialysis patients with CKD (on every 1 SD decrease in the uOC level, odds ratio 1.70, 95 % confidence interval
1.24–2.98, P < 0.01). Multivariate stepwise regression analysis demonstrated that decreased uOC level (β = -0.163, P < 0.05)
was an independent risk factor for increased carotid IMT in non-dialysis patients with CKD.
Conclusion: Serum uOC levels in non-dialysis patients with CKD are significantly lower than those in healthy individuals,
and uOC is closely associated with subclinical atherosclerosis in CKD patients.
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Background
The mortality rate of patients with chronic kidney disease
(CKD) is much higher than that of an age-matched general
population, with death caused by cardiovascular events
accounting for over 50 % of deaths. Atherosclerotic cardio-
vascular disease (CVD) is considered the most common
complication causing mortality in patients with CKD. Al-
though the incidences of traditional risk factors are high in
CKD patients, such as hypertension and diabetes, the high
mortality rate of CVD in these patients cannot yet be fully
explained [1–3].
Osteocalcin (OC) is a 49-amino acid, vitamin K-
dependent calcium-binding protein which was secreted by
mature osteoblasts. It is a specific biomarker of bone turn-
over and bone formation. OC plays a critical role in main-
taining the bone mineralization rate and inhibiting
hydroxyapatite crystallization and cartilage mineralization.
Recent studies have shown that OC might also be involved
in the regulation of energy, and glucose and lipid metabol-
ism [4]. OC knockout mice demonstrated impaired glu-
cose tolerance and clearly increased fat content as well as
fat quantity. However, administration of recombinant OC* Correspondence: prof_nizh@126.comRenal Division, Renji Hospital, School of Medicine, Shanghai Jiaotong
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promoted the proliferation of pancreatic ß cells, increased
insulin level, enhanced energy metabolism, increased insu-
lin sensitivity, and promoted adiponectin expression, sug-
gesting an interaction between bone tissue and metabolism
[5, 6]. In addition, multiple studies have demonstrated that
OC is closely associated with the development and progno-
sis of atherosclerosis and CVD [7–14].
Circulating total osteocalcin (tOC) is comprised of two
major forms of OC, undercarboxylated osteocalcin (uOC)
and carboxylated osteocalcin (cOC). Recent studies on
patients with hypertension and metabolic syndromes have
shown that uOC is closely associated with the develop-
ment of CVD [7, 8]. Alfadda et al. measured the levels of
all three forms of OC in patients with type 2 diabetes, and
found that uOC was a better predictor of CVD risk in
these patients than tOC [15]. Animal and in vitro studies
have shown that only the uOC elicits an endocrine
effect, which maintains glucose homeostasis and regu-
lates lipid metabolism [6]. The relationship between
uOC levels and atherosclerosis in the CKD population has
not been well investigated. Therefore, we performed a
cross-sectional study to investigate the relationship be-
tween uOC levels and carotid atherosclerosis in non-
dialysis patients with CKD.
Methods
Study subjects
Two hundred forty non-dialysis CKD patients (age, 50–
75 years; men and postmenopausal women) admitted
to our hospital were enrolled in this study. CKD is de-
fined as either kidney damage or glomerular filtration
rate (GFR) < 60 ml/min/1.73m2 for ≥ 3 months by the
National Kidney Foundation. Kidney damage is mani-
fested as pathologic abnormalities or markers of dam-
age, including abnormalities in blood or urine tests or
imaging studies. CKD patients can be divided into dif-
ferent stages according to the level of GFR: stage I
(GFR ≥ 90 ml/min/1.73m2), stage II (GFR 60–89 ml/
min/1.73m2), stage III (GFR 30–59 ml/min/1.73m2),
stage IV (GFR 15–29 ml/min/1.73m2) and stage V
(GFR < 15 ml/min/1.73m2). Exclusion criteria are as fol-
lows: (1) an acute cardio-vascular event (defined as acute
coronary syndrome, new-onset cardiac arrhythmia, heart
failure, cerebrovascular accident, peripheral vascular
thrombosis, or arterial dissection) within one month; (2)
infection or trauma within one month; (3) tumor; (4) famil-
ial hyperlipidemia; (5) acute exacerbation on CKD; (6)
autoimmune disease; and (7) diabetes. Fifty age and sex-
matched healthy individuals from the medical examination
center were included as control group. The procedures
used in this study met ethics requirements, and were ap-
proved by the ethics committee of Renji hospital. Informed
consent forms were signed by all participants.
Medical history collection
General characteristics of patients, including sex, age,
smoking history, medication use, height, body weight, and
body mass index (BMI) were recorded. Blood pressure
was measured in the morning with the patient in a supine
position after at least 10 min of rest using a sphygmoman-
ometer with a cuff wrapped around the left upper arm
positioned at the same level as the heart. The mean arter-
ial blood pressure (MABP) was calculated according to
the formula: MABP = diastolic blood pressure + 1/3 (sys-
tolic blood pressure − diastolic blood pressure).
Laboratory assessment
Blood samples were collected after a 10-h fast. Hemoglobin,
serum creatinine (Scr), blood urea nitrogen, uric acid, albu-
min, total cholesterol (TC), triglyceride (TG), high-density
lipoprotein cholesterol (HDL-C), low-density lipoprotein
cholesterol (LDL-C), fasting blood glucose (FBG), calcium,
and phosphorus levels were measured using an automatic
biochemistry analyzer (Bayer ADVIA 1650). High sensi-
tivity C-reactive protein (hs-CRP) level was measured by
rate nephelometry (Beckman Array 360 System, Deerfield,
IL, USA). Estimated GFR (eGFR) was calculated using
a MDRD-4 (Modification of Diet in Renal Disease
Study) formula: 186 × (Scr/88.4)-1.154 × age-0.203 × (0.742
if female) [16].
Analysis of serum uOC
Serum uOC level was measured using an enzyme-linked
immunosorbent assay (ELISA) (Takara Bio Inc., Japan).
The ELISA kit provides specific monoclonal antibodies
reactive to uOC at amino acid positions 17, 21, and 24.
The detection sensitivity was 0.25 ng/ml.
Doppler ultrasonography of the carotid artery
Doppler ultrasonography of the carotid artery was per-
formed by specialized professionals within one month of
blood sampling using an HP-HX Color Doppler Ultra-
sound System (Hewlett-Packard Company, Palo Alto,
CA, USA) with a 10 MHz transducer. The angle be-
tween the ultrasound beam and the direction of blood
flow was <60°, and the intima-media thickness (IMT)
was measured at 2 cm proximal to the bifurcation of the
carotid artery. IMT was defined as the distance between
the lumen-intima interface and the media-adventitia
interface. An atherosclerotic plaque was defined as an
echo-structure protruding into the vascular lumen with a
thickness of >1 mm and more than twice the thickness of
the neighboring sites [17]. Systolic peak velocity (SPV), dia-
stolic peak velocity (DV), and resistance index (RI) were
also determined.
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Statistical analysis
Quantitative variables were expressed as mean ± stand-
ard deviation or median (interquartile range). Two
groups of normally distributed data were compared
using an independent sample t-test, and the difference
among multiple groups was analyzed using single-factor
analysis of variance (ANOVA). A Mann–Whitney U
test was performed to analyze the difference between
two groups of non-normally distributed data, and the
Kruskal–Wallis test was performed to compare the dif-
ferences among multiple groups. The χ2 test was used to
compare the differences in data constitution. Correl-
ation analysis was performed using Pearson method.
Multivariate logistic regression analysis was performed
to investigate the relationship between uOC and carotid
plaques. Multivariate stepwise linear regression analysis
was performed to determine factors affecting carotid
IMT. All statistical analyses were performed using SPSS
software version 19.0, and P < 0.05 was considered sta-
tistically significant.
Results
General characteristics of non-dialysis patients with CKD
General characteristics of patients are presented in
Table 1. The main etiology of CKD included the follow-
ing: glomerulonephritis (n = 151, 62.92 %), hypertensive
nephrosclerosis (n = 25, 10.42 %), tubulointerstitial
nephritis (n = 7, 2.92 %), polycystic kidney disease (n = 2,
0.83 %), obstructive nephropathy (n = 2, 0.83 %), and CKD
of unknown cause (n = 53, 22.08 %). There were significant
differences in the levels of BMI, MABP, hemoglobin,
eGFR, uric acid, TC, TG, LDL-C, HDL-C, phosphate and
hs-CRP among different groups. As for the drug use, 97
(40.42 %) patients used angiotensin-converting enzyme in-
hibitor, 81 (33.75 %) patients used angiotensin receptor
blocker, 135 (56.25 %) patients used calcium channel
Table 1 Baseline characteristics of CKD patients
All CKD CKD I-II CKD III CKD IV CKD V P value
N 240 41 75 58 66
Age, year 61.83 ± 11.61 58.84 ± 12.44 60.96 ± 10.85 62.83 ± 11.41 63.82 ± 12.57 NS
Male, n (%) 151 (62.92 %) 30 (73.17 %) 54 (72.00 %) 33 (56.90 %) 34 (51.52 %) < 0.01
BMI, kg/m2 23.68 ± 4.14 24.23 ± 4.35 24.64 ± 4.16 22.34 ± 3.54 23.26 ± 4.12 < 0.01
Smoke history, n (%) 49 (20.42 %) 6 (14.63 %) 14 (18.67 %) 16 (27.59 %) 13 (19.70 %) NS
MABP, mmHg 100.67 (93.00–110.83) 95.33 (90.00–104.58) 96.67 (91.67–108.33) 103.33 (93.33–113.33) 103.67 (96.67–115.83) < 0.05
FBG, mmol/L 5.03 ± 0.84 4.81 ± 0.62 5.26 ± 0.90 4.73 ± 0.75 5.15 ± 0.89 NS
Hemoglobin, g/dl 110.45 ± 31.26 135.79 ± 28.37 126.43 ± 26.54 108.58 ± 18.46 83.89 ± 18.45 < 0.01
Albumin, g/L 37.90 (33.25–40.50) 38.00 (32.10–42.50) 37.50 (35.00–41.50) 36.25 (32.50–39.50) 36.00 (32.05–39.10) NS
eGFR, ml/min/1.73m2 20.05 (12.43–49.32) 83.57 (71.28–108.35) 44.56 (37.72–53.52) 24.53 (19.35–26.42) 8.17 (5.84–10.52) < 0.01
Uric acid, mmol/L 467.51 ± 133.13 354.72 ± 114.87 445.16 ± 98.76 494.32 ± 112.53 509.58 ± 157.19 < 0.01
TC, mmol/L 4.74 (4.11–5.89) 4.83 (4.17–5.69) 5.15 (4.13–6.18) 5.31 (4.27–6.36) 4.36 (3.65–5.23) < 0.01
TG, mmol/L 1.69 (1.22–2.52) 1.75 (1.12–2.59) 1.84 (1.26–2.87) 1.78 (1.36–2.51) 1.52 (1.12–2.16) < 0.01
LDL-C, mmol/L 3.14 (2.40–3.97) 3.24 (2.58–4.07) 3.39 (2.57–4.31) 3.22 (2.71–4.14) 2.82 (2.31–3.49) < 0.01
HDL-C, mmol/L 1.25 (1.02–1.49) 1.36 (1.13–1.64) 1.31 (1.00–1.58) 1.23 (1.12–1.53) 1.15 (1.03–1.56) < 0.01
Calcium, mmol/L 2.18 ± 0.28 2.22 ± 0.34 2.15 ± 0.24 2.09 ± 0.31 2.14 ± 0.25 NS
Phosphate, mmol/L 1.50 ± 0.42 1.29 ± 0.37 1.35 ± 0.44 1.54 ± 0.50 1.71 ± 0.62 < 0.01
hs-CRP, mg/L 2.24 (1.00–4.10) 1.80 (1.00–3.50) 1.84 (1.00–4.87) 2.36 (1.00–3.56) 3.64(2.03–5.84) < 0.01
Drug use
ACEI, n (%) 97 (40.42 %) 30(73.17 %) 31 (41.33 %) 23 (39.66 %) 13 (19.70 %) < 0.01
ARB, n (%) 81 (33.75 %) 17 (41.46 %) 28 (37.33 %) 19 (32.76 %) 17 (25.76 %) NS
CCB, n (%) 135 (56.25 %) 10 (24.39 %) 38 (50.67 %) 32 (55.17 %) 55 (83.33 %) < 0.01
β-blocker, n (%) 62 (25.83 %) 7 (17.07 %) 17 (22.67 %) 18 (31.03 %) 20 (30.30 %) NS
Statin, n (%) 47 (19.58 %) 5 (12.20 %) 23 (30.67 %) 11 (18.97 %) 8 (12.12 %) < 0.05
Phosphate binder, n (%) 58 (24.17 %) 0 (0 %) 7 (9.33 %) 13 (22.41 %) 38 (57.58 %) < 0.01
Active VitD, n (%) 14 (5.83 %) 0 (0 %) 0 (0 %) 3 (5.17 %) 11 (16.67 %) < 0.01
BMI body mass index, MABP mean arterial blood pressure, FBG fasting blood glucose, eGFR estimated glomerular filtration rate, TC total cholesterol, TG triglycerides, LDL-C
low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, hs-CRP high-sensitivity C-reactive protein, ACEI angiotensin-converting enzyme inhibitor,
ARB angiotensin receptor blocker, CCB calcium channel blocker, VitD vitamin D
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blocker, 62 (25.83 %) patients used β-blocker, 47 (19.58 %)
patients used statin, 58 (24.17 %) patients used phosphate
binder and 14 (5.83 %) patients used active Vitamin D.
B-mode ultrasonography findings of the carotid artery in
CKD patients
Carotid ultrasonography that was performed in all patients
showed carotid plaques in 124 (51.67 %) patients. Carotid
IMT gradually increased as eGFR decreased (P < 0.01). No
significant differences in the ratio of carotid plaque forma-
tion and levels of SPV, DV and RI were observed among
different groups of patients (Table 2).
Significant decrease in uOC level in CKD patients
The uOC levels in non-dialysis CKD patients were signifi-
cantly lower than those in healthy controls [28.16 (21.40–
45.85) ng/mL vs. 36.42 (28.05–49.28) ng/mL, P < 0.01].
The uOC levels gradually decreased as CKD progressed
(P < 0.01) (Fig. 1). Spearman’s correlation analysis demon-
strated a significant positive correlation of the uOC level
with eGFR (r = 0.48, P < 0.01) and HDL-C level (r =
0.43, P < 0.01) as well as a negative correlation with age
(r = -0.34, P < 0.01), uric acid (r = -0.22, P < 0.05), and
hs-CRP level (r = -0.36, P < 0.01) (Table 3).
Correlation between uOC level and carotid plaque formation
in CKD patients
The uOC levels were significantly lower in patients with
carotid plaques than in patients without carotid plaques
[25.98 (20.14–31.35) ng/mL vs. 31.02 (25.86–36.40) ng/
mL, P < 0.01]. Logistic regression analysis showed that
decreased uOC level indicated increased possibility of ca-
rotid plaque formation in non-dialysis CKD patients after
adjustment for age, sex, BMI, smoking history, MABP,
eGFR, therapeutic medication use, and FBG, TC, TG,
LDL-C, HDL-C, and hs-CRP levels (every 1 SD decrease
in uOC level, odds ratio 1.70, 95 % confidence interval
1.24–2.98, P < 0.01).
Correlation between uOC level and carotid IMT in CKD
patients
Univariate correlation analysis demonstrated that the
uOC level had a significant negative correlation with IMT
(r = -0.33, P < 0.01, Table 3). This correlation persisted
after adjustment for age (r = -0.28, P < 0.01). Likewise,
multivariate stepwise regression analysis showed that age
(β = 0.289, P < 0.01), hs-CRP level (β = 0.146, P < 0.05), and
uOC level (β = -0.163, P < 0.05) were independent risk fac-
tors for increased carotid IMT in non-dialysis CKD pa-
tients (Table 4). The original model included all variables
significantly associated with IMT on univariate analysis,
including age, BMI, hemoglobin, MABP, TC, TG, HDL-C,
eGFR, uric acid, hs-CRP and uOC.
Discussion
This cross-sectional study showed that serum uOC
levels in non-dialysis CKD patients were significantly
lower than those in healthy controls. The decrease in
uOC level was closely associated with the development
of carotid plaque, and was an independent risk factor for
increased IMT in CKD patients. In the general popula-
tion, previous study showed the negative correlation be-
tween uOC level and carotid atherosclerosis [18]. Our
study was consistent with the results of general popula-
tion, and expanded this association to the non-dialysis
CKD patient population. To our knowledge, the present
study is the first of its kind, and the results are valuable
for clarifying risk stratification of CVD in CKD patients.
A study on Korean postmenopausal women demon-
strated that tOC level was negatively correlated with
BMI [19]. Pittas et al. also reported a negative correl-
ation between tOC level and body fat content in a popu-
lation over 65 year old [20]. However, a correlation
between uOC level and BMI was not observed in this
study, which is similar to the previous studies [15], sug-
gesting that tOC and uOC might play different roles in
energy metabolism. Dyslipidemia has been recognized as
an independent risk factor for CVD. The main compo-
nents of atherosclerotic plaque are large amounts of
deposited cholesterol and cholesterol esters. Animal stud-
ies have shown that continuous subcutaneous infusion of
recombinant OC significantly improved serum lipid level
in wild type mice [6]. Our results demonstrated that
serum uOC level was positively correlated with HDL-C
level in non-dialysis CKD patients, indicating that uOC
might participate in the regulation of lipid metabolism.
Table 2 Carotid B-mode ultrasonography of CKD patients
All CKD CKD I-II CKD III CKD IV CKD V P value
N 240 41 75 58 66
Carotid plaque, n (%) 124 (51.67 %) 18 (43.90 %) 36 (48.00 %) 32 (55.17 %) 38 (57.58 %) NS
IMT (mm) 0.79 ± 0.23 0.66 ± 0.20 0.76 ± 0.29 0.83 ± 0.33 0.88 ± 0.30 < 0.01
SPV(cm/s) 78.49 ± 21.54 82.13 ± 18.05 79.96 ± 24.32 73.24 ± 17.78 79.75 ± 18.86 NS
DV(cm/s) 20.40 ± 8.12 25.23 ± 6.64 22.56 ± 8.41 22.14 ± 6.42 23.55 ± 7.24 NS
RI 0.72 ± 0.07 0.71 ± 0.11 0.72 ± 0.06 0.72 ± 0.06 0.74 ± 0.06 NS
IMT intima-media thickness, SPV systolic peak velocity, DV diastolic peak velocity, RI resistance index
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Studies on the correlation between OC level and CVD
have yielded various results. OC level has been reported
to show a significant negative correlation with brachial
ankle pulse wave velocity and IMT in patients with type
2 diabetes, and has been speculated to function as a pro-
tective factor against CVD [9]. Another study reported
that serum OC level was significantly lower in patients
with coronary heart disease (CHD) than in patients
without CHD, and that serum OC level was significantly
inversely correlated with the extent of coronary stenosis
[10]. In a young adult population, increased risk of CVD
has been observed in patients with lower OC level [11].
In contrast to these results, increased OC level was
shown to be associated with high incidence of carotid
atherosclerosis in postmenopausal women and patients
with type 2 diabetes [12–14]. The differences in these re-
sults can be explained by the varying degree of carboxyl-
ation of OC in the patients. A previous study showed
that only the undercarboxylated part of serum OC was
involved in the process of vascular calcification [21]. Re-
cent studies suggested that uOC could serve as a novel
Fig. 1 Relationship between uOC concentration and progression of CKD. uOC concentration decreased significantly with the progression of CKD
(P < 0.01). This figure is a “box and whisker plot”. The center (box) represents the middle 50th percentile of the data set and is derived using the
lower and upper quartile values. The median value (dark line) is displayed inside the box. The maximum and minimum values are displayed with
vertical lines (whiskers) connecting the points to the center box
Table 3 Correlations between uOC concentrations and clinical
and echocardiographic parameters
Parameter Spearman’s r P value
Age, year −0.34 < 0.01
BMI, kg/m2 0.10 NS
MABP, mmHg 0.04 NS
FBG, mmol/L −0.22 NS
Hemoglobin, g/dl 0.10 NS
Albumin, g/L 0.05 NS
eGFR, ml/min/1.73m2 0.48 < 0.01
Uric acid, mmol/L −0.22 < 0.05
TC, mmol/L 0.03 NS
TG, mmol/L −0.12 NS
LDL-C, mmol/L 0.08 NS
HDL-C, mmol/L 0.43 < 0.01
Calcium, mmol/L 018 NS
Phosphate, mmol/L 0.01 NS
hs-CRP, mg/L −0.36 < 0.01
IMT (mm) −0.33 < 0.01
SPV(cm/s) 0.25 < 0.05
DV(cm/s) 0.20 < 0.05
RI −0.24 < 0.01
uOC undercarboxylated osteocalcin, BMI body mass index, MABP mean arterial
blood pressure, FBG fasting blood glucose, eGFR estimated glomerular filtration rate,
TC total cholesterol, TG triglycerides, LDL-C low-density lipoprotein cholesterol,
HDL-C high-density lipoprotein cholesterol, hs-CRP high-sensitivity C-reactive protein,
IMT intima-media thickness, SPV systolic peak velocity, DV diastolic peak velocity, RI
resistance index
Table 4 Multivariate stepwise regression analysis for IMT
Dependent variable:IMT
Standardized β P
Age 0.289 < 0.01
lg (hs-CRP) 0.146 < 0.05
lg (uOC) −0.163 < 0.05
Output from a multivariate stepwise regression model which showed that uOC
was an independent marker for IMT
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biomarker for carotid atherosclerosis in patients with
hypertension or metabolic syndrome [7, 8]. The present
study also demonstrated that uOC level was lower in
CKD patients with carotid plaques and that uOC level
inversely correlated with IMT, indicating that uOC
might play a critical role in preventing carotid athero-
sclerosis and CVD in non-dialysis CKD patients.
Numerous reports indicate that bone-associated proteins
are involved in the process of atherosclerosis and calcifica-
tion. Bini et al. studied human carotid endarterectomy
specimens and showed that OC, osteopontin, and osteo-
nectin were expressed both in large calcified areas as well
as in small calcium deposits in atherosclerotic carotid
arteries [22]. Gossl et al. studied endothelial progenitor
cells (EPCs) in the circulating blood of patients with ath-
erosclerosis, and found that EPCs expressed high levels of
OC when they migrated to repair vascular injuries, and
promoted arterial calcification at the same time [23]. Simi-
lar results were obtained from animal studies. A study on
rapid aortic injury in rabbits induced by balloon angio-
plasty demonstrated that calcium deposits were found in
necrotic areas 2–4 days after the injury and that OC
expression was detected 14 days after vascular injury, indi-
cating that OC was involved in the regulation of athero-
sclerosis development [24]. Matrix Gla Protein (MGP) and
OC are well known Gla proteins. Rapid arterial calcifica-
tion developed in MGP knockout mice, suggesting that
MGP might be a key factor in the process of calcification
[25]. OC and MGP display the same expression profile in
humans. Therefore, OC and MGP, as Gla proteins, might
play critical roles in both bone mineralization and vascular
calcification. However, the underlying mechanisms by
which OC regulates atherosclerosis and calcification need
to be further studied.
Atherosclerosis is a chronic inflammatory process. CRP,
which is an acute phase reactant produced by the liver, is
not only a marker for CVD, but is also associated with the
development and progression of atherosclerosis. The re-
sults of this study demonstrated that serum uOC level had
a significant negative correlation with CRP level, indicat-
ing that the microinflammatory condition in CKD patients
might be involved in the development of atherosclerosis.
CRP not only regulates the aggregation of monocytes, but
also simulates the production of tissue factors, activates
complements and coagulation, thereby promoting forma-
tion and development of atherosclerotic plaques [26].
The limitations of this study are listed as follows. Firstly,
the causality between the decreased uOC level and devel-
opment of atherosclerosis could not be revealed through
this observational study. Due to the cross-sectional design,
the mechanism underlying the correlation between uOC
level and carotid atherosclerosis could not be elucidated.
Secondly, although numerous CVD risk factors such as
hypertension and hyperlipidemia were strictly controlled,
the possibility that underlying diseases and the corre-
sponding medications interfered with the results cannot
be ruled out. Finally, a prospective study with some clin-
ical endpoints is required to clarify the role of uOC in the
development of CVD in CKD patients.
Conclusions
This study showed that decreased uOC levels were closely
associated with carotid atherosclerosis in non-dialysis
CKD patients. uOC may be not only a simple indicator of
mineralization, but also an important factor that links
bone metabolism and CVD. Further study is needed to
determine if uOC could serve as a novel biomarker for
predicting atherosclerosis and CVD in CKD patients.
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